


Scaffolds for Alternative DELivery



Nanofitin[®]-based drug in Inflammatory Bowel Disease (IBD)

- A project supported by the European Commission through the Seventh Framework Programme (FP7)
- Nanofitins, a new class of non-antibody affinity ligands extremely stable
- **Administered by oral route to prevent from systemic-related side effects**
- Generated against TNF α , a target clinically validated in inflammatory bowel disorders
- Demonstrate of a **strong preventive and curative anti-inflammatory action in mice** models of Crohn and Ulcerative Colitis

Want to learn more? Come to see us at the
 "Managing the manageable: Chronic pain and fatigue" session
 Saturday, February 21, 2015 from 10:50 to 12:20 @ Plenary hall, Ground level

